Our expertise centers on the two fields of pharmacology and biology, where we have dedicated teams that aim to meet the specific demands of the companion animal, poultry, ruminant and swine sectors. We continually strive to find better solutions to existing and emerging diseases which will in turn improve animal health and productivity.
Our care extends beyond animal health and welfare, these days a staggering 75% of all emerging human infectious diseases are of animal origin. Ceva is involved in the fight against the spread of infectious disease that can be transmitted from wild or domestic animals and birds to humans – diseases known as zoonoses, which include avian flu, brucellosis and Q-fever.
Our global business operations are divided into six major zones: Western Europe, Central and Eastern Europe (incl. Turkey), North America, Latin America, Africa/Middle East and Asia/Pacific.
We have a presence in 42 countries, have 13 research and development centres, 21 production sites and more than 3000 employees worldwide. The company is focused on the research, development, production and marketing of pharmaceutical products and vaccines for companion animal, poultry, ruminant and swine.
*Source: Vetnosis, CAGR period 1999-2009